Integrilin: profile and news

Millennium and Johnson & Johnson Pharmaceutical Research & ...  07 Mar 2006
...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving ... - Yahoo! News (press release)

Eric Topol May Leave Cleveland Clinic  Feb 9, 2006
...people ), Plavix, from Sanofi-Aventis (nyse : SNY - news - people ), and both Eli Lilly's (nyse: LLY - news - people ) Reopro and Integrilin, from Millennium ... - Forbes

Thrombolytic Treatment Before Stenting Linked to Increased ...  Feb 14, 2006
There was no increase in mortality for patients pre-treated with glycoprotein IIb/IIIa inhibitors such as ReoPro (abciximab), Integrilin (eptifibatide), and ... - MedPage Today,

Schering Plough "peer perform," estimates reduced  Feb 1, 2006
...note published yesterday, the analyst mentions that the company's gross margins are expected to be adversely impacted in 2006 by the Integrilin royalty payments ... - New Ratings

Millennium Announces New Senior Vice President of Human Resources  09 Feb 2006
...in manufacturing the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide ... - PR Newswire (press release),

Eric Topol May Leave Cleveland Clinic  09 Feb 2006
...people ), Plavix, from Sanofi-Aventis (nyse : SNY - news - people ), and both Eli Lilly's (nyse: LLY - news - people ) Reopro and Integrilin, from Millennium ... - Forbes

Millennium Achieves 2005 Financial Guidance  Jan 26, 2006
...revenue of $123.5 million associated with the original collaboration agreement with Schering-Plough Corporation for INTEGRILIN® (eptifibatide) Injection. ... - Yahoo! News (press release)

Millennium Achieves 2005 Financial Guidance  Jan 26, 2006
...co-promotion revenue of $123.5 million associated with the original collaboration agreement with Schering-Plough Corporation for INTEGRILIN(R) (eptifibatide ... - PR Newswire (press release),

Schering-Plough posts profit, key drugs deliver  Jan 30, 2006
...the decline in the broader drug sector — due to lighter-than-expected revenue growth on lower sales for its anti-clotting treatment Integrilin and animal ... - ABC News

Schering-Plough Reports Financial Results for 2005 Fourth Quarter ...  Jan 30, 2006
...and commercialize golimumab with Centocor Inc., acquiring assets of NeoGenesis Pharmaceuticals and acquiring exclusive US rights to INTEGRILIN from Millennium ... - PR Newswire (press release),

Millennium Announces Appointments of Executive Vice President of ...  Jan 25, 2006
He joined Millennium in 2004 as the head of sales and marketing for INTEGRILIN® (eptifibatide) Injection, a product the Company sold the development and ... - Yahoo! News (press release)

Schering-Plough Swings to Profit  Jan 30, 2006
...primarily from product mix and supply chain process improvements, partly offset by the impact of the restructured agreement for Integrilin, which became ... - TheStreet.com

UPDATE 5-Schering-Plough posts profit, key drugs deliver  Jan 30, 2006
But the stock fell 2.5 percent due to lighter-than-expected revenue growth on lower sales for its anti-clotting treatment Integrilin and animal health business ... - Reuters

Schering-Plough Reports Financial Results For 2005  Jan 31, 2006
...primarily from product mix and supply chain process improvements, partly offset by the impact of the restructured agreement for INTEGRILIN, which became ... - CattleNetwork.com,

Schering Plough "peer perform," estimates reduced  Feb 1, 2006
...note published yesterday, the analyst mentions that the company's gross margins are expected to be adversely impacted in 2006 by the Integrilin royalty payments ... - New Ratings

Arginox Appoints Robert Terifay as President and Chief Operating ...  Jan 6, 2006
...for establishment of the company's commercial presence in the acute care cardiovascular market, taking the company's first product, INTEGRILIN(R) (eptifibatide ... - PR Newswire (press release),

New Data Show Median 30-Month Survival With VELCADE(R) (Bortezomib ...  12 Dec 2005
...in manufacturing the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide ... - PR Newswire (press release),

The Addition of INTEGRILIN(R) (Eptifibatide) Injection Achieved ...  Nov 14, 2005
...analysis of the CLEAR PLATELETS (Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets) study showed that adding INTEGRILIN(R), a potent ... - PR Newswire (press release),

Early Initiation Of INTEGRILIN(R) (Eptifibatide) for Heart-Attack ...  Nov 12, 2005
12 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that results from the Time to Integrilin Therapy in Acute Myocardial ... - PR Newswire (press release),

Early Initiation of Integrilin (Eptifibatide) for Heart-Attack ...  Nov 14, 2005
DALLAS, TX -- November 14, 2005 -- Schering-Plough Corporation announced that results from the Time to Integrilin Therapy in Acute Myocardial InfarctioN ... - DG News

Stent patients go home sooner if wrist artery used  Nov 13, 2005
...and Sanofi-Aventis . Their drug ReoPro competes with Merck & Co.'s similar anti-clot medicine Aggrastat and Schering-Plough Corp.'s Integrilin. ... - Reuters AlertNet,

POST OF THE DAY  Nov 23, 2005
...successful treatments. The bull case for the stock imagines a good future for Integrilin, a royalty cardiac drug for MLNM. As well ... - Motley Fool

(PRN) - Odimo Incorporated Announces Third Quarter 2005 Results .. ...  Nov 14, 2005
...[+]. (PRN) - Treecon Resources Releases Third Quarter Financial Information. ... [. PRN) - The Addition of INTEGRILIN(R) (Eptifibatide) Injection Achieved ... - Bolsamania.com,

US heart patients receive more transfusions than international ...  Nov 18, 2005
...to Open Occluded Coronary Arteries) IIb, PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy) and PARAGON ... - Medical News Today (press release),

(PRN) - Governor Perdue Proclaims November 15 SHARE Day ... [+]  Nov 14, 2005
...(PRN) - The Addition of INTEGRILIN(R) (Eptifibatide) Injection Achieved Superior Reduction in Inflammatory Markers TNF-Alpha and CRP Compared to a Commonly ... - Bolsamania.com,

Millennium, facing profit goal, weighs cost cutting  Sep 26, 2005
In July, Millennium announced it would give up co-promotion rights to its cardiovascular drug Integrilin with Schering Plough Corp. ... - MSNBC

Direct Thrombin Inhibitors: Not Ready for Prime Time?  08 Sep 2005
...coronary interventions, Angiomax (bivalirudin) may be superior to a combination of heparin and a glycoprotein IIb/IIIa inhibitor such as Integrilin or ReoPro ... - MedPage Today,

Millennium Initiates Phase II Clinical Trial to Evaluate MLN1202 ...  Aug 18, 2005
...company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a ... - PR Newswire (press release),

Millennium Sells Integrilin Rights In US To Schering  Jul 25, 2005
...restructured its collaboration for Integrilin, granting exclusive US development and commercialization rights to Schering-Plough Corp. ... - BioWorld Online (subscription)

Schering-Plough to Acquire From Millennium Exclusive US Marketing ...  Jul 22, 2005
...(Nasdaq: MLNM - News) today announced an agreement to restructure their collaboration for cardiovascular drug INTEGRILIN to optimize the growth potential of ... - Yahoo News (press release)

Schering-Plough to Acquire From Millennium Exclusive US Marketing ...  Jul 23, 2005
...and Millennium Pharmaceuticals (Nachrichten) today announced an agreement to restructure their collaboration for cardiovascular drug INTEGRILIN to optimize the ... - FinanzNachrichten.de

Schering-Plough to Acquire From Millennium Exclusive US Marketing ...  Jul 22, 2005
...today announced an agreement to restructure their collaboration for cardiovascular drug INTEGRILIN to optimize the growth potential of this US market-leading ... - RedNova.com

Millennium sells rights to heart drug Integrilin  Jul 23, 2005
Millennium Pharmaceuticals has agreed to sell additional rights to it's Integrilin heart drug. ... The deal eliminates 200 jobs, mostly Integrilin's sales force. ... - Providence Eyewitness News

Millennium Reports Second Quarter 2005 Financial Results  Jul 28, 2005
In addition, our newly restructured relationship with Schering-Plough Corporation for INTEGRILIN will provide us with substantial revenue and increased near ... - Yahoo News (press release)

Millennium deal worth as much as $255.5m  Jul 23, 2005
Millennium Pharmaceuticals Inc. said it agreed to sell additional rights to its Integrilin heart drug to Schering-Plough Corp. in ... - Boston Globe

Q2 2005 Millennium Pharmaceuticals Earnings Conference Call ...  Aug 2, 2005
2Q04. MLNM expects non-GAAP net loss of under $100m for 2005. Q&A Focus: INTEGRILIN, VELCADE, compendia, and trials. Corporate conference ... - Research and Markets (subscription)

Schering-Plough, Millennium change deal  Jul 22, 2005
Pharmaceuticals Inc. to obtain exclusive development and commercialization rights for the cardiovascular drug Integrilin. Millennium ... - BusinessWeek

Schering-Plough acquires rights to heart drug  Jul 26, 2005
Schering-Plough has reached a deal with Millennium Pharmaceuticals to acquire the heart drug Integrilin. The two companies have ... - Pharmaceutical Business Review

Millennium Pharma Outlook: 'The Worst Is Over'  Jul 25, 2005
Pharmaceuticals (nasdaq: MLNM - news - people ) after the specialty pharmaceutical firm announced last Friday it would divest the Integrilin heart drug to ... - Forbes

Schering-Plough Buys Drug Rights  Jul 25, 2005
Schering-Plough (SGP:NYSE - commentary - research) has acquired exclusive rights to the heart drug Integrilin from its partner Millennium Pharmaceuticals (MLNM ... - TheStreet.com

Millennium Pharma sees job cuts on Schering-Plough pact  Jul 25, 2005
...that the modified agreement, under which Schering-Plough acquires exclusive development and marketing rights for the cardiovascular drug Integrilin, will lead ... - Lakeland Ledger

Big Pharma Turns A Corner  Jul 30, 2005
..."We think the transfer of US rights for Integrilin to Schering-Plough (nyse: SGP - news - people ) is long-term strategic positive," it said. ... - Forbes

Schering-Plough, Millennium alter clot-drug deal  Jul 22, 2005
...(MLNM.O: Quote, Profile, Research) $35.5 million and future drug royalties for the right to take over marketing of anti-clotting drug Integrilin, which they ... - Reuters

Millennium Pharma Pressured By Celgene's Revlimid  Jul 28, 2005
...estimate as well. "We think the transfer of US rights for Integrilin to Schering-Plough is long-term strategic positive.". The research ... - Forbes

Millennium Pharmaceuticals "neutral," estimates raised  Jul 25, 2005
In a research note published this morning, the analysts mention that the company has transferred its commercial responsibilities for the Integrilin product to ... - New Ratings

Millennium Pharma sees job cuts on Schering-Plough pact  Jul 25, 2005
Corporation. That deal gives Schering-Plough exclusive development and marketing rights for a cardiovascular drug called Integrilin. ... - Providence Eyewitness News

UPDATE 1-Schering-Plough, Millennium alter clot-drug deal  Jul 22, 2005
Research) an upfront payment of $35.5 million and future drug royalties for the right to take over marketing of anti-clotting drug Integrilin, which they have ... - Reuters

Maytag, D&K Healthcare, Adams, more  Jul 23, 2005
Schering-Plough Corp. (SGP: news, chart, profile) has agreed to acquire the exclusive US marketing rights for Integrilin from Millennium Pharmaceuticals Inc. ... - MarketWatch

Movers & Shakers  Jul 25, 2005
Schering-Plough Corp. (SGP: news, chart, profile) agreed to acquire the exclusive US marketing rights for cardiovascular drug Integrilin from its collaboration ... - MarketWatch

Stocks to Watch Ace Ltd., American Express, Netflix  Jul 23, 2005
Schering-Plough Corp. (SGP: news, chart, profile) has agreed to acquire the exclusive US marketing rights for cardiovascular drug Integrilin from its ... - MarketWatch

Eye On Stocks For Thursday, July 28  Jul 27, 2005
...last Friday Schering-Plough (nyes: SGP - news - people ) agreed to acquire the exclusive developmental and marketing rights of heart drug Integrilin for $35.5 ... - Forbes

Eye On Stocks For Monday, July 25  Jul 22, 2005
...an agreement with Millennium Pharmaceuticals (nasdaq: MLNM - news - people ) to obtain sole developmental and marketing rights for Integrilin, a heart drug ... - Forbes

Highlights of rising and falling US stocks  Jul 25, 2005
...(SGP) agreed to acquire the exclusive US marketing rights for cardiovascular drug Integrilin from its collaboration partner, Millennium Pharmaceuticals Inc. ... - Investor's Business Daily (subscription)

Ace, Netflix, American Express  Jul 24, 2005
SGP) has agreed to acquire the exclusive US marketing rights for cardiovascular drug Integrilin from its collaboration partner, Millennium Pharmaceuticals Inc. ... - Investor's Business Daily (subscription)

US Stock-Index Futures Little Changed; American Express Falls  Jul 25, 2005
...rose in extended trading after Schering-Plough Corp. agreed to buy exclusive US marketing rights to its drug Integrilin, used in angioplasty procedures. ... - Bloomberg

Stocks set to open down before earnings  Jul 25, 2005
Late Friday, Schering-Plough Corporation said it agreed to acquire exclusive US rights to develop and market Integrilin, a cardiovascular drug that it co ... - BusinessWeek

US Stock-Index Futures Are Little Changed; Xerox Declines  Jul 25, 2005
...climbed 32 cents to $10.25. Schering-Plough Corp. agreed to buy exclusive US marketing rights to Millennium's cardiovascular drug Integrilin. ... - Bloomberg

US Stock-Index Futures Are Little Changed; Xerox Shares Drop  Jul 25, 2005
Schering-Plough Corp. agreed to buy exclusive US marketing rights to Millennium's cardiovascular drug Integrilin. Schering- Plough added 73 cents to $20.69. ... - Bloomberg

Millennium Pharma Revenue Falls  Jul 28, 2005
Plough (SGP:NYSE - commentary - research) and Millennium agreed to transfer exclusive US commercialization and development rights for Integrilin to Schering ... - TheStreet.com

Millennium rally leads late trade  Jul 22, 2005
Schering-Plough (SGP) said after the bell that it has agreed to acquire the exclusive US marketing rights for cardiovascular drug Integrilin from collaboration ... - Investor's Business Daily (subscription)

US pre-open: US stocks to start low  Jul 25, 2005
After the bell on Friday, Schering-Plough said it acquired US rights to develop and market cardiovascular drug Integrilin, which it co-promotes with Millennium ... - ShareCast

Millennium Pharmaceuticals to Webcast Conference Call on Second ...  Jul 22, 2005
...company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a ... - PharmaLive.com (press release)

Street Chatter: Quality Systems, Nu Skin Enterprises, and ...  Jul 28, 2005
...cardiovascular disorders. Its flagship drug INTEGRILIN is FDA-approved to treat various unstable angina and heart surgery candidates. The ... - Schaeffers Research

14th annual report: Top 100 biotechnology companies  Jul 11, 2005
...patients. The company also markets Integrilin, a glycoprotein IIb/IIIa platelet aggregation inhibitor for acute coronary syndrome. ... - Med Ad News (subscription)

Biomed Rounds: A look at recent happenings among life science ...  Jul 18, 2005
Millennium hired some of the brightest scientists in the region, and their work helped produce Velcade, a cancer drug, and Integrilin, a cardiovascular ... - Boston Mass High Tech